LOTTE (004990) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
23 Jun, 2026Executive summary
Revenue declined by 4.1% year-over-year to KRW 3.59 trillion, with operating profit dropping 74.1% to KRW 17.95 billion and net income turning to a loss of KRW 91.87 billion, reflecting a significant decline in profitability.
The group’s main business segments include retail, chemicals, food, and beverages, with diversified global operations.
Global F&B sales grew, but domestic consumption slowdown and cost pressures reduced profitability.
The company maintains a strong liquidity position, with cash and cash equivalents at KRW 1.24 trillion as of March 31, 2025.
Financial highlights
Consolidated operating margin fell from 1.9% to 0.5% year-over-year.
Q1 2025 consolidated sales: KRW 3.59 trillion (down from KRW 3.74 trillion in Q1 2024).
Operating income: KRW 17.95 billion (Q1 2024: KRW 69.34 billion).
Net loss attributable to owners: KRW 109.74 billion (Q1 2024: loss of KRW 43.88 billion).
Debt ratio increased to 152.6% from 146.3% at year-end.
Outlook and guidance
Enhancement projects and business restructuring in retail aim for performance turnaround.
F&B division targets global expansion and product innovation, including new store launches in the US.
Ongoing investments in hydrogen, battery materials, and recycling are expected to support future growth.
The company aims to maintain a stable dividend policy and enhance shareholder returns through buybacks and capital management.
Latest events from LOTTE
- H1 2026 revenue reached KRW 15.54 trillion with a return to net profitability and strong liquidity.004990
Q2 2026 - Operating profit surged 156% year-over-year as F&B growth offset retail restructuring.004990
Q1 2026 - 4Q25 saw stable revenue, wider operating loss, improved net loss, and higher shareholder returns.004990
Q4 2025 - Targeting 35%+ shareholder return rate and growth via new businesses and ESG leadership.004990
Corporate Value-up Plan presentation - H1 2025: Revenue KRW 15.76T, net loss KRW 160.4B, debt ratio 149.4%, positive 2H25 outlook.004990
Q2 2025 - Record sales offset by profit decline from higher costs and affiliate losses; growth plans continue.004990
Q4 2024 - H1 2024 saw record revenue but a net loss due to equity losses and chemical headwinds.004990
Q2 2024 - Record revenue but net loss due to cost pressures; major biologics investments continue.004990
Q3 2024 - 3Q25 revenue was KRW 4,154B, with a net loss of KRW -283.9B and a 156.1% debt ratio.004990
Q3 2025